KEGG   DRUG: Crofelemer
Entry
D03605                      Drug                                   
Name
Crofelemer (USAN);
Fulyzaq (TN);
Mytesi (TN)
Product
MYTESI (Napo Pharmaceuticals)
Remark
ATC code: A07XA06
Product: D03605<US>
Efficacy
Antidiarrheal
Comment
For the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy
Target
CFTR (ABCC7) [HSA:1080] [KO:K05031]
CLCA [HSA:1179 9635 22802] [KO:K05027 K05028 K05030]
  Pathway
hsa04924  Renin secretion
hsa04971  Gastric acid secretion
hsa04972  Pancreatic secretion
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
   A07X OTHER ANTIDIARRHEALS
    A07XA Other antidiarrheals
     A07XA06 Crofelemer
      D03605  Crofelemer (USAN) <US>
USP drug classification [BR:br08302]
 Gastrointestinal Agents
  Anti-diarrheal Agents
   Crofelemer
    D03605  Crofelemer (USAN)
Target-based classification of drugs [BR:br08310]
 Ion channels
  Other ion channels
   Chloride channel
    CLCA
     D03605  Crofelemer (USAN) <US>
 Transporters
  ABC transporters
   ABCC subfamily
    CFTR (ABCC7)
     D03605  Crofelemer (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03605
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03605
Other DBs
CAS: 148465-45-6
PubChem: 17397714
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system